FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

94 letters match. Newest first.

  1. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  2. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  3. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  4. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  5. Ridley USA Inc.

    Ridley USA's Iowa City medicated feed plant put monensin into cattle feed instead of the intended drug, killing at least 16 cattle.

    High risk
  6. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  7. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  8. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  9. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  10. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  11. Pro Numb Tattoo Numbing Spray, LLC

    FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.

    High risk
  12. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  13. Apollo Care, LLC

    FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.

    High risk
  14. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  15. Chemco Corporation

    FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.

    High risk
  16. Barcelona Nut Company Inc.

    Barcelona Nut Company in Baltimore found rodent and insect contamination and allergen cross-contact in ready-to-eat nuts and seeds.

    High risk
  17. Medline Industries, LP

    Medline's Glen Falls, NY plant made angiographic syringes and kits under flawed CAPA, cleaning and design verification controls, FDA says.

    High risk
  18. Physitemp Instruments, LLC

    FDA says Physitemp sold clinical thermometers and temperature probes without FDA clearance and with unvalidated sterilization and welding.

    High risk
  19. Yangzhou H&R Plastic Daily Chemical Co., Ltd.

    Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.

    High risk
  20. IsoTis OrthoBiologics, Inc.

    IsoTis OrthoBiologics in Irvine, CA failed to properly fix and assess possible particulate contamination in its Accell bone filler devices, FDA says.

    High risk
  21. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  22. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  23. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  24. Avertix Medical, Inc.

    FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.

    High risk
  25. Simtra BioPharma Solutions

    FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.

    High risk
  26. Tentamus India Private Limited

    FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.

    High risk
  27. Raw Bistro Inc.

    FDA warns Raw Bistro that its raw dog food contained Salmonella Paratyphi and its pathogen controls were inadequate.

    High risk
  28. Diasol, Inc.

    Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.

    High risk
  29. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  30. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  31. Bio-Medical Pharmaceutical Manufacturing Corporation

    Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.

    High risk
  32. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  33. Cohance Lifesciences Limited

    Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.

    High risk
  34. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  35. Flextronics America LLC

    FDA warns Flextronics America, contract maker of FreeStyle Libre 3 glucose sensors in Austin, TX, over an unvalidated assembly step and weak corrective actions.

    High risk
  36. Abbott Diabetes Care, Inc.

    FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

    High risk
  37. Unomedical Device S.A. de C.V.

    FDA warns Unomedical over insulin infusion sets with unvalidated leak tests and unreported serious injuries.

    High risk
  38. Meridian Bioscience, Inc

    FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.

    High risk
  39. Integrity Partners Group

    FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

    High risk
  40. Winder Laboratories, LLC

    FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.

    High risk
  41. Absolutely Natural

    FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.

    High risk
  42. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  43. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  44. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk